Forbes)
Heart attack survivors saw no reduction in cardiovascular death and heart failure using sacubitril/valsartan (Entresto) compared with ramipril, Novartis said. More details on the PARADISE-MI trial are to be announced at the American College of Cardiology meeting later this month. (
FiercePharma)
Switching to high-sensitivity cardiac troponin testing in the emergency department was associated with more findings of myocardial injury and MI, but no overall increase in resource use (except angiography), a health system found in its Wisconsin hospitals. (
Journal of the American College of Cardiology)
Meanwhile, Roche listed new ways to use its cardiac troponin T and N-terminal pro-brain natriuretic peptide tests in identifying a person s cardiovascular risk.
With heart failure, good nutrition could mean survival
Personalised dietary advice reduces risk of death for hospitalised patients.
Credit: Justin Paget/Getty Images.
A Swiss study has shown that personalised nutrition support for people hospitalised with chronic heart failure reduced their risk of dying compared to those given standard hospital food.
Patients with malnutrition were most likely to benefit, which is unsurprising given it’s well established that malnutrition is associated with poorer patient outcomes – including people with heart failure.
The study randomised more than 600 people admitted to eight hospitals with chronic heart failure to nutrition support aimed at meeting their energy, protein and micronutrient needs or to a control group offered normal hospital food.
The
Impedimed Limited(ASX: IPD) share price is bouncing this morning after the company announced positive progress in its SOZO technology for heart patients.
The Impedimed share price has been seesawing between the opening price of 12 cents and its current price of 12.5 cents per share, up 4.1%.
Founded and headquartered in Brisbane with US and European operations, Impedimed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology, specifically its SOZO test, to help predict potential heart failure and prevent edemas and hospital readmission.
Impedimed is marketing its SOZO technology to US hospitals as a way of diagnosing the potential risk of future fluid overload in heart failure patients before they’re released.
(rilonacept) launched as the first and only FDA-approved therapy for recurrent pericarditis -
- Mavrilimumab Phase 2 severe COVID-19 data demonstrated a reduction in mechanical ventilation and death at Day 29; Phase 3 enrollment ongoing -
- Final KPL-404 Phase 1 data support further development in patients; Phase 2 proof-of-concept trial initiation planned for 2H 2021 -
- Cash reserves of approximately $264 million -
HAMILTON, Bermuda, May 04, 2021 (GLOBE NEWSWIRE) Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today reported first quarter 2021 financial results and recent corporate and portfolio activity.
New analysis of EXPLORER-HCM trial assessing impact of mavacamten on patient’s health status to be presented as late-breaking oral presentation Interim results of EXPLORER long-term extension study of mavacamten safety and efficacy data in patients with obstructive hypertrophic cardiomyopathy also to be presented Bristol Myers Squibb today announced that data from multiple studies across the company’s clinical … New analysis of EXPLORER-HCM trial assessing impact of mavacamten on patient’s health status to be presented as late-breaking oral presentation Interim results of EXPLORER long-term extension study of mavacamten safety and efficacy data in patients with obstructive hypertrophic cardiomyopathy (oHCM)